These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 29490769

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
    Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, Bousquet J.
    Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
    [Abstract] [Full Text] [Related]

  • 4. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
    Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G.
    Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.
    Ilyina NI, Edin AS, Astafieva NG, Lopatin AS, Sidorenko IV, Ukhanova OP, Khanova FM.
    Int Arch Allergy Immunol; 2019 Jan; 178(3):255-263. PubMed ID: 30677766
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
    Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W.
    Allergy Asthma Proc; 2012 Jan; 33(4):324-32. PubMed ID: 22856633
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intranasal spray medications for maintenance therapy of allergic rhinitis.
    Berger WE, Meltzer EO.
    Am J Rhinol Allergy; 2015 Jan; 29(4):273-82. PubMed ID: 26132312
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
    Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, Kasran A, Talavera K, Wouters MM, Ceuppens JL, Seys SF, Hellings PW.
    Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy.
    Watts AM, West NP, Smith PK, Zhang P, Cripps AW, Cox AJ.
    Immun Inflamm Dis; 2022 Mar; 10(3):e571. PubMed ID: 34813682
    [Abstract] [Full Text] [Related]

  • 17. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children.
    Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A, Valovirta E, Wickman M, Wahn U.
    Allergy; 2016 Aug; 71(8):1219-22. PubMed ID: 27043452
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis.
    Segall N, Prenner B, Lumry W, Caracta CF, Tantry SK.
    Allergy Asthma Proc; 2019 Sep 01; 40(5):301-310. PubMed ID: 31248471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.